Varenicline should be used as a first-line treatment to help smokers with mental illness quit

Journal of Dual Diagnosis

Volumn 8, Issue 2, 2012, Pages 113-116

  Williams, Jill M ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE PATCH; VARENICLINE;

ABNORMAL DREAMING; AGITATION; ANXIETY; DEPRESSION; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART DEATH; HUMAN; INSOMNIA; LIFE EXPECTANCY; MENTAL DISEASE; NAUSEA; NOTE; PRIMARY MEDICAL CARE; PSYCHOSIS; SCHIZOPHRENIA; SMOKING CESSATION; SUICIDAL BEHAVIOR; TOBACCO DEPENDENCE; UNITED KINGDOM; WITHDRAWAL SYNDROME;

EID: 84861375048     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1080/15504263.2012.670848     Document Type: Note

References (37)

1. Anghelescu, I. (2009). Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient. The Journal of Neuropsychiatry and Clinical Neuroscience, 21 (1), 102-103. doi:10.1176/appi.neuropsych.21.1.102
2. Aubin, H-J., Bobak, A., Britton, J. R., Oncken, C., Billing Jr., C. B., Gong, J., Reeves, K. R. (2008).Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised, open-label trial. Thorax, 63 (8), 717-724. doi:10.1136/thx.2007.090647
3. Breslau, N., Schultz, L. R., Johnson, E. O., Peterson, E. L., & Davis, G. C. (2005). Smoking and the risk of suicidal behavior: A prospective study of a community sample. Archives of General Psychiatry, 62 (3), 328-334. doi:10.1001/archpsyc.62.3.328 (Pubitemid 40990978)
4. Brown, S., Inskip, H., & Barraclough, B. (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212-217. doi:10.1192/bjp.177.3.212
5. Cahill, K., Stead, L. F., & Lancaster, T. (2011). Nicotine receptor partial agonists for smoking cessation. The Cochrane Database of Systematic Reviews, 2, CD006103. doi:10.1002/14651858.CD006103.pub2
6. Centers for Disease Control and Prevention. (2007). Cigarette smoking among adults-United States, 2006. MMWR Morbidity and Mortality Weekly Report, 56 (44), 1157-1161.
7. Clarke, D. E., Eaton, W. W., Petronis, K. R., Ko, J. Y., Chatterjee, A., & Anthony, J. C. (2010). Increased risk of suicidal ideation in smokers and former smokers compared to never smokers: Evidence from the Baltimore ECA Follow-Up Study. Suicide & Life-threatening Behavior, 40 (4), 307-318. doi:10.1521/suli.2010.40.4.307
8. Coe, J.W.,Brooks, P.R.,Vetelino, M. G.,Wirtz, M. C.,Arnold, E. P.,Huang, J., O'Neill, B. T. (2005). Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry, 48 (10), 3474-3477. doi:10.1021/jm050069n (Pubitemid 40664098)
9. Eisenberg, M. J., Filion, K. B., Yavin, D., Belisle, P., Mottillo, S., Joseph, L., Pilote, L. (2008). Pharmacotherapies for smoking cessation: A metaanalysis of randomized controlled trials. Canadian Medical Association Journal, 179 (2), 135-144. doi:10.1503/cmaj.070256 (Pubitemid 352020119)
10. Evins, A. E., & Goff, D. C. (2009). Varenicline treatment for smokers with schizophrenia: A case series. Journal of Clinical Psychiatry, 69 (6), 1016. (Pubitemid 351944959)
11. Fatemi, S. H. (2008). Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophrenia Research, 103 (1-3), 328-329. doi:10.1016/ j.schres.2008.05.002
12. Fiore, M. C., Jéen, C. R., Baker, T. B., Bailey, W. C., Benowitz, N. L., Curry, S. J. Wewers, M. E. (2009). Treating tobacco use and dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service.
13. Freedman, R. (2007). Exacerbation of schizophrenia by varenicline. American Journal of Psychiatry, 164 (8), 1269. doi:10.1176/appi.ajp.2007. 07020326 (Pubitemid 47292423)
14. Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., Reeves, K. R. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA: The Journal of the American Medical Association, 296 (1), 47-55. doi:10.1001/jama.296.1.47
15. Gunnell, D., Irvine, D.,Wise, L., Davies, C., & Martin, R. M. (2009). Varenicline and suicidal behaviour: A cohort study based on data from the General Practice Research Database. British Medical Journal, 1, 339. doi:10.1136/bmj.b3805
16. Hagman, B. T., Delnevo, C. D., Hrywna, M., & Williams, J. M. (2008). Tobacco use among those with serious psychological distress: Findings from the National Survey of Drug Use and Health, 2002. Addictive Behaviors, 33 (4), 582-592. doi:10.1016/j.addbeh.2007.11.007
17. Han, E. S., Foulds, J., Steinberg, M. B., Gandhi, K. K., West, B., Richardson, D. L., Dasika, J. (2006). Characteristics and smoking cessation outcomes of patients returning for repeat tobacco dependence treatment. International Journal of Clinical Practice, 60 (9), 1068-1074. doi: 10.1111/j.1742-1241.2006.01077.x (Pubitemid 44226744)
18. Hughes, J. R. (2006). Clinical significance of tobacco withdrawal. Nicotine & Tobacco Research, 8 (2), 153-156. doi:10.1080/14622200500494856 (Pubitemid 43675071)
19. Jorenby, D. E.,Hays, J. T., Rigotti, N. A., Azoulay, S.,Watsky, E. J.,Williams, K. E., Reeves, K. R. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: A randomized controlled trial. JAMA: The Journal of the American Medical Association, 296 (1), 56-63. doi:10.1001/jama.296.1.56
20. Kelly, D. L., McMahon, R. P., Wehring, H. J., Liu, F., Mackowick, K. M., Boggs, D. L., Dixon, L. (2011). Cigarette smoking and mortality risk in people with schizophrenia. Schizophrenia Bulletin, 37 (4), 832-838. doi:10.1093/schbul/sbp152
21. Kutscher, E. C., Stanley, M., & Oehlke, K. (2009). Chantix-induced mental status changes in a young healthy female. South Dakota Medicine, 62 (5), 193, 195.
22. Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D., & Bor, D. H. (2000). Smoking and mental illness: A populationbased prevalence study. JAMA: The Journal of the American Medical Association, 284 (20), 2606-2610. doi:10.1001/jama.284.20.2606
23. Lichtermann, D., Ekelund, J., Pukkala, E., Tanskanen, A., & Lonnqvist, J. (2001). Incidence of cancer among persons with schizophrenia and their relatives. Archives of General Psychiatry, 58, 573-578. doi:10.1001/archpsyc.58.6.573 (Pubitemid 32523737)
24. McClure, J. B., Swan, G. E., Catz, S. L., Jack, L., Javitz, H., McAfee, T., Zbikowski, S. M. (2010). Smoking outcome by psychiatric history after behavioral and varenicline treatment. Journal of Substance Abuse Treatment, 38 (4), 394-402. doi:10.1016/j.jsat.2010.03.007
25. Miller, B. J., Paschall, C. B. III, & Svendsen, D. P. (2006).Mortality and medical comorbidity among patients with serious mental illness. Psychiatric Services, 57 (10), 1482-1487. doi:10.1176/appi.ps.57.10. 1482 (Pubitemid 44671660)
26. Moore, T. J., Glenmullen, J., & Furberg, C. D. (2010). Thoughts and acts of aggression/violence toward others reported in associationwith varenicline. Annals of Pharmacotherapy, 44 (9), 1389-1394. doi:10.1345/aph.1P172
27. Moriya, F., Hashimoto, Y., & Furumiya, J. (2007). Nicotine and cotinine levels in body fluids of smokers who committed suicide. Forensic Science International, 168 (2-3), 102-105. doi:10.1016/j.forsciint.2006.06.049 (Pubitemid 46617842)
28. Ostacher, M. J., Nierenberg, A. A., Perlis, R. H., Eidelman, P., Borrelli, D. J., Tran, T. B. Sachs, G. S. (2006). The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. Journal of Clinical Psychiatry, 67, 1907-1911. doi:10.4088/JCP. v67n1210 (Pubitemid 46048187)
29. Oquendo, M. A., Bongiovi-Garcia, M. E., Galfalvy, H., Goldberg, P. H., Grunebaum, M. F., Burke, A. K., & Mann, J. J. (2007). Sex differences in clinical predictors of suicidal acts after major depression: A prospective study. American Journal of Psychiatry, 164, 134-141. doi:10.1176/appi.ajp.164.1. 134 (Pubitemid 46154792)
30. Pachas, G. N., Cather, C., Pratt, S. I., Hoeppner, B., Nino, J., Carlini, S. V., Evins, A. E. (2012). Varenicline for smoking cessation in schizophrenia: Safety and effectiveness in a 12-week, open-label trial. Journal of Dual Diagnosis, 8, 117-125. doi:10.1080/15504263.2012.663675
31. Piper, M. E., Smith, S. S., Schlam,T.R., Fleming, M. F.,Bittrich,A. A., Brown, J. L., Baker, T. B. (2010). Psychiatric disorders in smokers seeking treatment for tobacco dependence: Relations with tobacco dependence and cessation. Journal of Consulting and Clinical Psychology, 78 (1), 13-23. doi:10.1037/a0018065
32. Smith, R. C., Lindenmayer, J. P., Davis, J. M., Cornwell, J., Noth, K., Gupta, S., Lajtha, A. (2009). Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research, 110 (1-3), 149-155. doi:10.1016/j.schres.2009.02.001
33. Stapleton, J. A., Watson, L., Spirling, L. I., Smith, R., Milbrandt, A., Ratcliffe, M., & Sutherland, G. (2008). Varenicline in the routine treatment of tobacco dependence: A pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction, 103 (1), 146-154. doi:10.1111/j.1360-0443.2007.02083.x (Pubitemid 350233424)
34. Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010). Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: A pooled analysis. Drug Safety, 33 (4), 289-301. doi:10.2165/11319180-000000000-00000
35. Tsoi, D. T., Porwal, M., & Webster, A. C. (2010). Interventions for smoking cessation and reduction in individuals with schizophrenia. The Cochrane Database of Systematic Reviews, 6, CD007253. doi:10.1002/14651858.CD007253
36. Williams, J. M., Steinberg,M. B., Steinberg,M. L., Gandhi, K. K., Ulpe, R., & Foulds, J. (2011). Review of varenicline for tobacco dependence: Panacea or plight? Expert Opinion on Pharmacotherapy, 12 (11), 1799-1812.
37. Wu, P.,Wilson, K., Dimoulas, P., & Mills, E. J. (2006). Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BioMed Central Public Health, 6, 300.